# DEA Judge Rejects Anti-Rescheduling Plea to Reopen Cannabis Hearing, Allows New Briefs – Cannabis Business Times > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/ced-advancing-clinical-pain-management-and-remote-2026-10-22/ > **Published:** 2026-10-22T21:33:41-04:00 | **Last Modified / Clinically Audited:** 2026-10-22T21:33:41-04:00 > **Clinical Summary:** cannabis news digest: CED Clinic analysis of 3 recent cannabis policy, science, and regulatory developments with Dr. Benjamin Caplan. --- CED Clinical Relevance #65 Verified Overview Curated multi-source overview preserving 3 verified developments. Clinical Insight | CED Clinic Managing chronic pain after major orthopedic surgery remains a significant challenge, as traditional opioids often fail to provide adequate relief while introducing risks of dependency. The McMaster pilot study addresses a specific clinical gap for the one in four patients who suffer from persistent pain after total knee arthroplasty. Simultaneously, the move toward remote monitoring via oral fluid tests reflects a shift toward more precise, data-driven patient management. These clinical advancements occur against a backdrop of regulatory change, where the DEA’s refusal to delay rescheduling hearings suggests a steady, if slow, progression toward a new federal framework for cannabis. DigestCannabis NewsRegulationPublic HealthClinical Practice AudiencePatients, clinicians, healthcare professionals, regulators, and industry researchers. Primary TopicClinical and policy analysis: DEA Judge Rejects Anti-Rescheduling Plea to Reopen Cann. Source[Read the full source](https://clinicaltrials.gov/study/NCT06891235) Table of Contents - [DEA Judge Rejects Anti-Rescheduling Plea to Reopen Cannabis Hearing, Allows New Briefs – Cannabis Business Times](#DEA_Judge_Rejects_Anti-Rescheduling_Plea_to_Reopen_Cannabis_Hearing_Allows_New_Briefs_8211_Cannabis_Business_Times)[How to Interpret This Cannabis News & Regulatory Digest](#How_to_Interpret_This_Cannabis_News_Regulatory_Digest)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading) - [CED Perspective Lens: Eight Viewpoints on These Updates](#CED_Perspective_Lens_Eight_Viewpoints_on_These_Updates)[Understanding Your Recovery Options](#Understanding_Your_Recovery_Options) - [Integrating New Evidence into Practice](#Integrating_New_Evidence_into_Practice) - [Objective Monitoring for Better Outcomes](#Objective_Monitoring_for_Better_Outcomes) - [The Path to Federal Rescheduling](#The_Path_to_Federal_Rescheduling) - [Modernizing Study Designs](#Modernizing_Study_Designs) - [Evaluating the Limits of Current Data](#Evaluating_the_Limits_of_Current_Data) - [Supporting Recovery with New Tools](#Supporting_Recovery_with_New_Tools) - [The Future of Cannabis Medicine](#The_Future_of_Cannabis_Medicine) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) # DEA Judge Rejects Anti-Rescheduling Plea to Reopen Cannabis Hearing, Allows New Briefs – Cannabis Business Times A structured CED Clinic overview of 3 key developments in cannabis regulation, market milestones, and scientific research. What This Study Teaches Us A Phase 3 pilot RCT at McMaster University evaluates cannabinoids against placebo for the 25 percent of 75,000 annual knee replacement patients who develop persistent post-surgical pain. Boston Children’s Hospital is recruiting 200 individuals aged 18 to 35 for a virtual study to validate oral fluid testing as a remote metric for cannabis use frequency. Administrative law proceedings continue as a DEA judge maintains the current hearing schedule while allowing new legal briefs on the proposed shift to Schedule III. Why This Matters Validating remote oral fluid testing provides clinicians with objective tools to monitor patient adherence and usage patterns without requiring in-person clinic visits. Establishing the efficacy of cannabinoids for post-surgical pain offers a potential alternative to opioid therapy for the significant portion of patients experiencing long-term recovery complications. Study SnapshotPost TypeCannabis News & Regulatory Digest using canonical CED layoutItems Reviewed3 verified updatesPrimary DatesOctober 22, 2026Related Reading3 verified live CED Clinic internal linksUpdate 1Study of an Oral Fluid (Boston Children’s Hospital Regulatory Analysis)Update 2Cannabinoids vs. Placebo on Persistent (McMaster University Regulatory Analysis)Update 3DEA Judge Rejects Anti-Rescheduling Plea (Google News Federal & State Policy Regulatory Analysis) Clinical Bottom Line This clinical and regulatory overview preserves key signals across 3 updates without overstatement, offering grounded guidance for patients and practitioners. Context Across These 3 Updates This curated cannabis news & regulatory digest brings together 3 key developments across policy movements, regulatory milestones, and public health communications. Reviewing these distinct updates side by side clarifies emerging patterns while preserving the specific clinical context of each report. Examining these developments concurrently helps clinicians, patients, and families trace the broader trajectory of the field while grounding practical decisions in verified primary data. Update 1: Study of an Oral Fluid Testing Approach **Title & Source:** [Clinical Trial: Study of an Oral Fluid Testing Approach](https://clinicaltrials.gov/study/NCT06891235) (*Boston Children’s Hospital*, 2026-10-22) **Lead Authors & Identifiers:** Boston Children’s Hospital. Content lane: **Protocol Watch**. **Regulatory Context:** This virtual study recruits 200 adults to evaluate oral fluid testing as a remote method for measuring cannabis use frequency. It aims to provide a biologic alternative to self-reported data for researchers and clinicians. **Operative Findings:** The study focuses on individuals using cannabis at least once weekly to validate the accuracy of oral fluid markers. It establishes a framework for conducting large-scale cannabis research without the need for traditional site visits. **Clinical Relevance:** Remote testing could simplify the process of tracking patient adherence in clinical practice. This technology may eventually help clinicians correlate specific usage patterns with therapeutic outcomes. **Practical Boundaries:** The study is limited to a younger demographic and relies on the accuracy of home-collected samples. Update 2: Cannabinoids vs. Placebo on Persistent Post-surgical Pain Following **Title & Source:** [Clinical Trial: Cannabinoids vs. Placebo on Persistent Post-surgical Pain Following TKA: A Pilot RCT](https://clinicaltrials.gov/study/NCT03825965) (*McMaster University*, 2026-10-22) **Lead Authors & Identifiers:** McMaster University. Content lane: **Clinical Evidence Update**. **Regulatory Context:** This Phase 3 pilot RCT compares cannabinoids to placebo for persistent pain in patients following total knee arthroplasty. The study addresses the 25 percent of patients who do not find relief through standard surgical recovery. **Operative Findings:** The trial investigates whether cannabinoids can reduce the reliance on opioids for post-surgical pain management. It targets a cohort of 75,000 annual surgical patients in Canada to improve quality of life and employment outcomes. **Clinical Relevance:** Clinicians should look to this data for evidence-based alternatives to opioids in orthopedic recovery. The results may help define specific cannabinoid ratios or doses for post-surgical applications. **Practical Boundaries:** As a pilot study, the initial sample size may not capture rare side effects or varied patient responses. Update 3: DEA Judge Rejects Anti-Rescheduling Plea to Reopen Cannabis **Title & Source:** [DEA Judge Rejects Anti-Rescheduling Plea to Reopen Cannabis Hearing, Allows New Briefs – Cannabis Business Times](https://news.google.com/rss/articles/CBMi7wFBVV95cUxOUzY3NzlUMzZZNmZsNEJldDE1MkpKOFJoUklYNVRWN0JHNk9qWWtDUEl1XzJLN3JYcXV3aTJFSldyVi11Mmw3YkVrUnAxOERuZFVLLXIwY3dHWmhZeHJmM0RDcGllTWdLWnVndG5CckdjYWxCQ3M2SWRyU0xXYnlvZjRvM1lYcXEtZHdLbHp0QXVvRmRraUphTDV6ZFR1WDFHOVpWVVFBenJubW5rVXAwdDFCdUQ3d0xzeEJkRnVXUzVab1lZZlREakkwQzhfZlIyNC1zRjF5MW05dmxBQ2NiRlBoVlNtMjYyaVZqZ1JxVQ?oc=5) (*Google News Federal & State Policy*, 2026-10-22T17:09:20+00:00) **Institutional Review & Source:** Google News Federal & State Policy Policy Analysis. Content lane: **Evidence Check**. **Regulatory Context:** A DEA administrative judge recently denied a request to reopen hearings for groups opposing the rescheduling of cannabis to Schedule III. The judge allowed for the submission of new legal briefs while keeping the overall process moving forward. **Operative Findings:** This ruling prevents further delays in the administrative review of the Department of Justice’s rescheduling proposal. It maintains the momentum of the federal effort to recognize the medical value of cannabis. **Clinical Relevance:** Stay informed on these rulings as they will eventually dictate the legal requirements for prescribing and research. Rescheduling will likely reduce the administrative hurdles currently faced by medical professionals. **Practical Boundaries:** This is a procedural ruling and does not represent a final decision on the legal status of cannabis. How Strong Is This Evidence? The McMaster study is a Phase 3 pilot randomized controlled trial, which represents a high level of clinical evidence for evaluating treatment efficacy. The Boston Children’s study uses a community sample of 200 participants to establish biologic measures, providing a moderate foundation for diagnostic validation. Regulatory updates from the DEA reflect administrative procedural steps rather than empirical scientific data. Where This Paper Deserves Skepticism Pilot studies often have smaller sample sizes that may limit the generalizability of findings to broader, more diverse patient populations. Remote, self-administered testing in the Boston study relies on participant compliance and may introduce variables that are harder to control than in a laboratory setting. Legal and administrative rulings are subject to political shifts and do not guarantee specific clinical outcomes or immediate changes in prescribing laws. What This Paper Does Not Show These studies do not prove that cannabinoids are superior to opioids for all types of post-surgical pain or that oral fluid testing is as accurate as blood analysis. The DEA’s procedural decisions do not confirm that rescheduling will occur by a specific date or define the final regulatory requirements for clinicians. How This Fits With the Broader Clinical Conversation The integration of cannabis into mainstream surgical recovery protocols represents a significant shift in how we approach persistent pain. For years, the medical community has sought alternatives to the standard opioid-centric model, especially for procedures like total knee arthroplasty where recovery is often marred by chronic discomfort. By investigating cannabinoids in a Phase 3 environment, researchers are treating these compounds with the same rigor as conventional pharmaceuticals. This scientific maturation coincides with a push for better monitoring tools. As cannabis becomes a more common component of a patient’s regimen, the ability to track usage patterns remotely becomes essential for safety and dose optimization. The development of oral fluid tests allows for a less invasive, more frequent assessment of how patients are utilizing their medicine in real-world settings. Editorial Commentary *In my experience, patients who undergo major joint replacements are often the most motivated to find non-opioid options. They see the headlines about the opioid crisis and feel a genuine sense of trepidation about their recovery plan. Seeing a formal Phase 3 trial dedicated to this specific cohort is encouraging because it validates the concerns of these patients and provides a path toward evidence-based alternatives.* *The move toward remote testing is equally practical. We often struggle to get accurate usage data from patients because memory is fallible and self-reporting can be biased. A biologic measure that can be done at home removes the friction of clinic visits and gives us a clearer picture of the relationship between dose frequency and clinical outcomes. It moves the conversation from subjective recall to objective data.* *Regarding the DEA updates, the administrative process is often slow for those on the front lines. However, the refusal to reopen hearings for anti-rescheduling pleas suggests that the momentum is staying on track. We are moving toward a reality where the federal government acknowledges the medical utility of this plant, which will eventually ease the burdens on both research and patient access.* What a Careful Reader Should Take Away Clinicians should monitor the results of the McMaster TKA trial as a potential guide for post-surgical cannabinoid protocols while recognizing that federal rescheduling remains a work in progress. Remote oral fluid testing may soon offer a practical way to track patient usage patterns with greater objectivity than self-reporting alone. [https://cedclinic.com/ask](https://cedclinic.com/ask)Ask about this study:[💢Pain](https://cedclinic.com/ask)[🧸Children and Teens](https://cedclinic.com/ask)[🏛️Law and Policy](https://cedclinic.com/ask)[🔎This study's limits](https://cedclinic.com/ask) Evidence Interpretation Guide ## How to Interpret This Cannabis News & Regulatory Digest These updates bridge the gap between rigorous clinical trials for pain, new diagnostic technologies for monitoring, and the evolving federal legal landscape. ### Three Rules for Critical Reading **Distinguish Between Pilot and Definitive Data**Recognize that the McMaster trial is a pilot study designed to test feasibility and initial efficacy before larger, multi-center trials are conducted. **Value Objective Monitoring Tools**Consider how remote oral fluid testing could replace subjective patient diaries to provide more accurate data on cannabis consumption habits. **Separate Procedure from Policy**Understand that DEA judge rulings are about the legal process of rescheduling and do not change the current legal status of cannabis for patients today. Key Evaluation Question How will the validation of remote testing tools change the way we supervise patients who use cannabis for chronic post-surgical pain? The Patient Question If I am planning for a knee replacement, can we discuss how cannabinoids might fit into my recovery plan based on this new research? The Bottom Line We are seeing a simultaneous advancement in clinical pain research, patient monitoring technology, and the federal regulatory framework. CED Perspective Lens ## CED Perspective Lens: Eight Viewpoints on These Updates Why these developments matter across clinical, patient, safety, and policy perspectives Lens OverviewEight distinct clinical and regulatory perspectives on DEA Judge Rejects Anti-Rescheduling Plea to R. #### Understanding Your Recovery Options Patients facing surgery often worry about the long-term impact of pain and the risks of opioid use. This research offers hope that more natural alternatives are being studied with the same rigor as standard medications. Knowing that doctors are looking for better ways to monitor and treat pain can provide a sense of security during a difficult recovery process. The possibility of using cannabinoids instead of traditional narcotics could lead to a recovery with fewer side effects. As researchers validate these treatments, patients gain more options for managing their health. This progress ensures that the choices available to you are based on solid science rather than guesswork, making the path to wellness clearer and more predictable. Lens takeawayNew research is focusing on making your post-surgical recovery safer and more effective through cannabinoid options. #### Integrating New Evidence into Practice We are often caught between the need for effective pain management and the risks of traditional analgesics. The McMaster trial provides the kind of high-level data needed to justify incorporating cannabinoids into a surgical recovery plan. These findings help bridge the gap between anecdotal patient reports and the rigorous standards of modern orthopedic medicine. The development of remote monitoring tools like oral fluid tests will help us manage these patients with greater precision and less administrative burden. By moving toward objective data, we can better tailor dosages and monitor for potential issues without requiring frequent office visits. This evolution supports a more professionalized approach to cannabis in a clinical setting. Lens takeawayRigorous trials and better monitoring tools are making it easier to integrate cannabis into standard clinical workflows. #### Objective Monitoring for Better Outcomes Safety in cannabis medicine depends on our ability to accurately track what patients are doing. The Boston Children’s study into oral fluid testing is a major step toward objective safety monitoring that does not require invasive blood draws. This allows for more frequent check-ins and a better understanding of how different usage levels affect a patient’s health. Using biologic markers instead of self-reported diaries reduces the risk of errors in patient care. When we have clear data on usage frequency, we can more accurately assess the risk of side effects or drug interactions. This focus on objective measurement is essential for maintaining the highest standards of patient safety as cannabis use becomes more common. Lens takeawayObjective monitoring through oral fluid tests will significantly improve our ability to ensure patient safety. #### The Path to Federal Rescheduling The DEA’s recent procedural decisions indicate a commitment to the rescheduling process despite significant opposition. By refusing to reopen hearings for anti-rescheduling pleas, the administrative judge is ensuring that the process moves toward a conclusion based on the existing record. This suggests a more stable path toward federal recognition of cannabis as a legitimate medical treatment. While the legal process is complex, these rulings prevent unnecessary delays that could stall progress for years. As the federal framework shifts, we expect to see a reduction in the barriers that currently hinder research and clinical practice. Staying informed on these administrative steps is vital for understanding the future of medical cannabis regulation. Lens takeawayFederal rescheduling efforts are maintaining momentum despite attempts by opposition groups to delay the process. #### Modernizing Study Designs Conducting cannabis research has historically been difficult due to regulatory barriers and the logistical challenges of in-person monitoring. The shift toward virtual trials and remote biologic testing, as seen in the Boston study, represents a modernization of the research field. These methods allow for larger, more diverse cohorts and more frequent data collection, leading to more robust findings. By utilizing technology to reach patients where they are, researchers can gather real-world data that is often more applicable than results from a controlled lab environment. This approach also makes participation easier for patients, which can lead to higher retention rates and more complete datasets. These innovations are setting a new standard for how we study cannabis. Lens takeawayVirtual study designs and remote testing are modernizing cannabis research and improving data quality. #### Evaluating the Limits of Current Data While pilot studies and procedural rulings are positive signs, they are not definitive proof of efficacy or immediate legal change. A pilot RCT is only the first step, and we must wait for larger trials to confirm these initial findings before changing standard care. We should remain cautious about over-interpreting results from small cohorts or preliminary administrative decisions. Similarly, the DEA’s legal maneuvers are complex and could still face significant hurdles before any rescheduling is finalized. Procedural wins do not always translate into immediate policy shifts, and the clinical community must remain patient. It is important to balance optimism with a realistic understanding of the time required for scientific and legal consensus. Lens takeawayMaintain a cautious outlook until pilot data is confirmed by larger trials and rescheduling is officially enacted. #### Supporting Recovery with New Tools For those caring for patients after major surgery, managing pain is often the most stressful part of the job. The possibility of using cannabinoids instead of opioids could mean fewer side effects like confusion or constipation for the patient. This research provides caregivers with more information to discuss alternative pain management strategies with the medical team. Better monitoring tools also mean that caregivers can have more productive conversations with doctors about how the patient is actually responding to treatment. Having objective data from oral fluid tests can take the guesswork out of tracking a patient’s progress. This clarity helps caregivers feel more confident in the care they are providing during the recovery process. Lens takeawayNew treatments and monitoring tools could make the caregiving process smoother and safer for everyone involved. #### The Future of Cannabis Medicine The convergence of clinical trials, new monitoring technology, and regulatory progress points toward a more professionalized future for cannabis medicine. Patients and clinicians alike stand to benefit from the increased clarity and safety that these developments provide. This shift ensures that cannabis is treated with the same scientific and legal respect as any other therapeutic option. As we move forward, the focus will remain on validating these treatments through rigorous study and ensuring they are accessible through a clear federal framework. Staying informed on these changes is essential for anyone navigating the current medical landscape. The progress we see today is a foundation for a more integrated and evidence-based approach to patient care. Lens takeawayThe professionalization of cannabis medicine is accelerating through better research, technology, and federal policy. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care [Dr. Benjamin Caplan, MD](https://cedclinic.com/drcaplan/) Board-Certified Family Physician • Cannabinoid Specialist • 350k+ Patients Evaluated A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Meet Dr. Caplan (CV)](https://cedclinic.com/drcaplan/) [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](http://CEDclinic.com/book) [Cannabis Care](http://CEDclinic.com/book) [https://cedclinic.com/drcaplan/](https://cedclinic.com/drcaplan/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=DEA+Judge+Rejects+Anti-Rescheduling+Plea+to+Reopen+Cannabis+Hearing%2C+Allows+New+Briefs+-+Cannabis+Business+Times&url=https%3A%2F%2Fcedclinic.com%2Fced-advancing-clinical-pain-management-and-remote-2026-10-22%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fced-advancing-clinical-pain-management-and-remote-2026-10-22%2F) [BlueSky](https://bsky.app/intent/compose?text=DEA+Judge+Rejects+Anti-Rescheduling+Plea+to+Reopen+Cannabis+Hearing%2C+Allows+New+Briefs+-+Cannabis+Business+Times%20https%3A%2F%2Fcedclinic.com%2Fced-advancing-clinical-pain-management-and-remote-2026-10-22%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Primary Sources: Boston Children's Hospital, McMaster University, Google News Federal & State Policy](https://clinicaltrials.gov/study/NCT06891235) Related Reading at CED ClinicContinue exploring the evidence[Cannabinoids for Low Back Pain and Migraine: What Randomized Trials Actually Show](https://cedclinic.com/ced-cannabinoids-for-low-back-pain-and-2026-09-23/) More on this topic: Rigorous physician appraisal of randomized trials investigating cannabinoid efficacy for chronic pain and migraines. [More on this topic: Chronic pain & migraine](https://cedclinic.com/ced-cannabinoids-for-low-back-pain-and-2026-09-23/)[THC Testing After Childbirth Can Trigger Child-Welfare Consequences](https://cedclinic.com/thc-testing-new-mothers-child-welfare/) More on this topic: Evidence-based breakdown of perinatal drug screening, hospital reporting policies, and downstream child protective services involvement. [More on this topic: Perinatal screening & welfare](https://cedclinic.com/thc-testing-new-mothers-child-welfare/)[The Multifaceted Impact of CBD on Sleep: A Comprehensive Guide for Better Rest](https://cedclinic.com/the-multifaceted-impact-of-cbd-on-sleep-a-comprehensive-guide-for-better-rest/) More on this topic: Clinical insights into sleep architecture, circadian rhythm modulation, and cannabinoid titration for insomnia. [More on this topic: Cannabinoids & sleep](https://cedclinic.com/the-multifaceted-impact-of-cbd-on-sleep-a-comprehensive-guide-for-better-rest/) ## Frequently Asked Questions What is covered in this cannabis news & regulatory digest? This edition reviews 3 verified developments across cannabis policy, regulatory oversight, and clinical science. How are stories selected for CED digests? Stories are curated from official primary sources, government agency dockets, and peer-reviewed journals, focusing on practical relevance for patients and clinicians. Do preliminary reports establish medical efficacy? No. Observational reports, preprints, and regulatory filings describe emerging trends and require formal clinical trials before treatment efficacy can be claimed. How should clinicians use these updates? Clinicians can use these updates to understand patient questions, stay current with state regulations, and maintain evidence-informed counseling. Where can readers find Dr. Caplan's clinical insights? Dr. Caplan provides comprehensive clinical perspectives, patient consultations, and educational resources at CEDclinic.com. Why are multi-topic digests published instead of single stories? Digests group related updates together to provide a broader thematic overview while preserving important nuances and methodological limits. What is the primary role of laboratory testing in cannabis policy? Laboratory testing verifies cannabinoid potency and screens for harmful contaminants like heavy metals, pesticides, and molds to protect consumer health. How do state regulatory milestones impact patient access? Administrative milestones establish the licensing rules, product categories, and retail standards that determine how and where registered patients obtain care. What precautions should families take with medical cannabis at home? Families should keep all medical cannabis products securely locked in child-resistant containers and clearly labeled to avoid accidental exposure. How often does CED Clinic publish clinical and policy updates? CED Clinic publishes regular morning, afternoon, and evening evidence reviews and news digests to keep the community informed. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).